Sarepta is also going way outside of antisense therapies to find treatment for DMD - CRISPR, gene therapy, utrophin modulation - they already have 6 clinical trials underway.
Heap of companies now in the DMD space really not sure how much room is left there for johnny come latelys even if ANP end up starting a trial - $1B market to a very small population.
Surely the company is better off trying to take one of the other drugs they've spent years trying to sell off further rather than another diversion.
600%, page-32
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
